Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 20, 2021 01:15 ET | Source: Novartis Pharma AG

Novartis provides an update on Phase III ligelizumab (QGE031) studies in chronic spontaneous urticaria (CSU)

Ad hoc announcement pursuant to Art. 53 LR Ligelizumab, a high-affinity anti-IgE antibody, demonstrated superiority compared with placebo at Week 12 in Phase III PEARL 1 and PEARL...
December 16, 2021 01:00 ET | Source: Novartis Pharma AG

Novartis initiates new USD 15 billion share buyback highlighting confidence in growth and pipeline

Ad hoc announcement pursuant to Art. 53 LR Share buyback of up to USD 15bn planned to be executed by end 2023, highlighting confidence in top line growth and deep pipelineSales expected to grow...
December 13, 2021 14:45 ET | Source: Novartis Pharma AG

Novartis announces T-Charge™, next-generation CAR-T platform with first-in-human data at ASH 2021

T-Charge, a next-generation platform that aims to revolutionize CAR-T cell therapy, will serve as foundation for various investigational CAR-T therapies Early data from first-in-human dose-escalation...
December 11, 2021 16:00 ET | Source: Novartis Pharma AG

Novartis Scemblix® demonstrates sustained response rate in 48-week follow-up in patients with chronic myeloid leukemia

Updated 48-week data from Phase III ASCEMBL trial consistent with improved major molecular response (MMR) rate of Scemblix® (asciminib) vs. Bosulif®* (bosutinib) and lower discontinuation rate due to...
December 11, 2021 12:00 ET | Source: Novartis Pharma AG

Novartis Kymriah® demonstrates strong responses in high-risk patients with relapsed or refractory follicular lymphoma in extended study follow-up

Complete and overall response rates and durability of response were well maintained across majority of high-risk subgroups with a significant unmet need1 Median follow-up of approximately 17 months...
December 10, 2021 08:00 ET | Source: Novartis Pharma AG

Novartis data highlight efficacy of Piqray® in HR+/HER2- metastatic breast cancer with a PIK3CA driver mutation immediately post-CDK4/6i

New data underscore efficacy of Piqray, even in those patients with a short treatment duration on prior CDK4/6i or with ESR1 mutations, biomarkers of endocrine resistance1-5 Recent guideline updates...
December 08, 2021 09:30 ET | Source: Novartis Pharma AG

New Kisqali® data shows consistent overall survival benefit across genomic and clinical subtypes of interest in HR+/HER2- metastatic breast cancer

Data from the MONALEESA Phase III program provide further evidence of the unique profile of Kisqali, the CDK4/6 inhibitor with the longest reported median overall survival (OS) in HR+/HER2- metastatic...
December 02, 2021 01:15 ET | Source: Novartis Pharma AG

Novartis R&D day spotlights attractive growth profile, underpinned by strong in-market brands, 20 potential high value pipeline assets, and technology platforms

Focused medicines company delivering strong operational performanceBuilding depth in five core therapeutic areas, strength in technology platforms, and a balanced geographic footprint Confident to...
November 04, 2021 10:00 ET | Source: Novartis Pharma AG

New data at ASH spotlight Novartis recently approved Scemblix®, next-generation CAR-T platform and expanding hematology portfolio

New longer-term efficacy and safety data from pivotal Phase III ASCEMBL study for recently US-approved Scemblix® (asciminib) in patients with PH+ CML-CPEarly findings from YTB323 and PHE885 CAR-T cell...
November 04, 2021 02:00 ET | Source: Novartis Pharma AG

Novartis verkauft ihre Roche-Beteiligung in einer bilateralen Transaktion an Roche

Ad-hoc-Mitteilung gemäss Art. 53 KR Novartis und Roche vereinbaren bilaterale Transaktion zum Verkauf von Roche-Inhaberaktien im Besitz von Novartis zu einem Gesamtpreis von USD 20,7 Mrd. Der...